Fig. 1

The effect of SOX2 on hypoxia-induced breast cancer cell migration. (a) MDA-MB-231 and MDA-MB-468 cells were incubated under hypoxia for the indicated times. Cellular lysates were assayed for SOX2 expression using western blotting. SOX2 was quantified and normalized against β-actin. *p < 0.05, **p < 0.01, referring to the difference between cells incubated with or without hypoxia. (b) Cells were transfected with siCtrl or siSOX2 for 48 h, then total protein extracts from cells transfected with siSOX2 were analyzed via western blotting for SOX2. SOX2 was quantified and normalized against β-actin. *p < 0.05, **p < 0.01, referring to the difference between cells treated with siCtrl or siSOX2. (c) The migratory capacity of cells transfected with siSOX2 under hypoxia for 12 h was evaluated using a wound-healing assay. (n = 10) *p < 0.05. (d) The migratory capacity of MDA-MB-231 cells transfected with siSOX2 under hypoxia for 12 h was evaluated using a transwell assay. *p < 0.05, **p < 0.01